ALGN
Price
$133.68
Change
+$1.40 (+1.06%)
Updated
Nov 19 closing price
Capitalization
9.6B
76 days until earnings call
Intraday BUY SELL Signals
COO
Price
$72.15
Change
-$0.05 (-0.07%)
Updated
Nov 19 closing price
Capitalization
14.35B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALGN vs COO

Header iconALGN vs COO Comparison
Open Charts ALGN vs COOBanner chart's image
Align Technology
Price$133.68
Change+$1.40 (+1.06%)
Volume$1.05M
Capitalization9.6B
Cooper Companies (The)
Price$72.15
Change-$0.05 (-0.07%)
Volume$3.51M
Capitalization14.35B
ALGN vs COO Comparison Chart in %
ALGN
Daily Signal:
Gain/Loss:
COO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALGN vs. COO commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and COO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ALGN: $133.73 vs. COO: $72.16)
Brand notoriety: ALGN: Notable vs. COO: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALGN: 84% vs. COO: 128%
Market capitalization -- ALGN: $9.6B vs. COO: $14.35B
ALGN [@Pharmaceuticals: Other] is valued at $9.6B. COO’s [@Pharmaceuticals: Other] market capitalization is $14.35B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $200.16B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALGN’s FA Score shows that 0 FA rating(s) are green whileCOO’s FA Score has 0 green FA rating(s).

  • ALGN’s FA Score: 0 green, 5 red.
  • COO’s FA Score: 0 green, 5 red.
According to our system of comparison, ALGN is a better buy in the long-term than COO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALGN’s TA Score shows that 5 TA indicator(s) are bullish while COO’s TA Score has 4 bullish TA indicator(s).

  • ALGN’s TA Score: 5 bullish, 4 bearish.
  • COO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALGN is a better buy in the short-term than COO.

Price Growth

ALGN (@Pharmaceuticals: Other) experienced а -5.62% price change this week, while COO (@Pharmaceuticals: Other) price change was -0.46% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.03%. For the same industry, the average monthly price growth was -0.29%, and the average quarterly price growth was +8.18%.

Reported Earning Dates

ALGN is expected to report earnings on Feb 04, 2026.

COO is expected to report earnings on Dec 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-2.03% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COO($14.3B) has a higher market cap than ALGN($9.6B). COO has higher P/E ratio than ALGN: COO (35.39) vs ALGN (25.92). COO YTD gains are higher at: -21.505 vs. ALGN (-35.864). COO has higher annual earnings (EBITDA): 1.09B vs. ALGN (793M). ALGN has more cash in the bank: 901M vs. COO (125M). ALGN has less debt than COO: ALGN (123M) vs COO (2.48B). COO (4.05B) and ALGN (3.97B) have equivalent revenues.
ALGNCOOALGN / COO
Capitalization9.6B14.3B67%
EBITDA793M1.09B73%
Gain YTD-35.864-21.505167%
P/E Ratio25.9235.3973%
Revenue3.97B4.05B98%
Total Cash901M125M721%
Total Debt123M2.48B5%
FUNDAMENTALS RATINGS
ALGN vs COO: Fundamental Ratings
ALGN
COO
OUTLOOK RATING
1..100
715
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6381
PRICE GROWTH RATING
1..100
6361
P/E GROWTH RATING
1..100
8185
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALGN's Valuation (75) in the Medical Specialties industry is in the same range as COO (76). This means that ALGN’s stock grew similarly to COO’s over the last 12 months.

ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as COO (100). This means that ALGN’s stock grew similarly to COO’s over the last 12 months.

ALGN's SMR Rating (63) in the Medical Specialties industry is in the same range as COO (81). This means that ALGN’s stock grew similarly to COO’s over the last 12 months.

COO's Price Growth Rating (61) in the Medical Specialties industry is in the same range as ALGN (63). This means that COO’s stock grew similarly to ALGN’s over the last 12 months.

ALGN's P/E Growth Rating (81) in the Medical Specialties industry is in the same range as COO (85). This means that ALGN’s stock grew similarly to COO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALGNCOO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
62%
Momentum
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
65%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
60%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 8 days ago
59%
Declines
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 15 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
75%
Aroon
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
52%
View a ticker or compare two or three
Interact to see
Advertisement
ALGN
Daily Signal:
Gain/Loss:
COO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FFOX27.020.17
+0.63%
Fundx Future Fund Opportunities ETF
DGZ5.710.03
+0.59%
DB Gold Short ETN
XDSQ39.780.12
+0.31%
Innovator US Eq Acltd ETF™ Quarterly
BSMQ23.650.03
+0.13%
Invesco BulletShares 2026 Muncpl Bd ETF
VTES101.45-0.08
-0.08%
Vanguard Short-Term Tax-Exmpt Bd ETF

ALGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALGN has been loosely correlated with BAX. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ALGN jumps, then BAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALGN
1D Price
Change %
ALGN100%
+1.10%
BAX - ALGN
65%
Loosely correlated
-2.53%
NVST - ALGN
57%
Loosely correlated
-0.94%
XRAY - ALGN
53%
Loosely correlated
-1.61%
LUNG - ALGN
52%
Loosely correlated
-1.07%
SAUHY - ALGN
49%
Loosely correlated
N/A
More